What Will New Weight Loss Medicines Bring to People with Type 2 Diabetes?
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.5 Articles
5 Articles
Researchers are also investigating whether the treatment can limit weight regain after stopping GLP-1 drugs. A new injectable drug, CBL-514, which selectively targets fat cells and causes them to die, appears to reduce both subcutaneous and visceral fat. The new data on the drug were presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan. CBL-514 induces selective apoptosis, i.e. controlled “death” …
What will new weight loss medicines bring to people with type 2 diabetes?
While the new generation of available weight management medications are the most effective we’ve ever had, there is still more to be desired: more health improvements, less gastrointestinal side effects, and for some people, needing medications that give more weight loss. A whack of new data in people with type 2 diabetes was just presented/published […]
An experimental injection could open up a completely different path than today's well-known slimming drugs. Instead of acting The article New Fat Drug, the injection that eliminates adipocytes comes from daily Blitz.
CBL-514 induces selective apoptosis, i.e. controlled “death” of fat cells, without affecting other cells. The new injectable therapy CBL-514, which selectively targets fat cells and causes them to die, appears to reduce both subcutaneous and visceral fat. The new data on the drug were presented at the annual conference of the European Association for the Study of Diabetes (EASD) in Milan. CBL-514 induces selective apoptosis, i.e. controlled “dea…
Sawalev has detected experimental weight reduction injections that help remove subcutaneous fat, while reducing the ingestionary fat surrounding internal organs associated with high risk of heart disease and diabetes. The drug CBL-514 is operating with a mechanism that differs from widespread weight reduction drugs such as Uigovi and Mongaro, where it targets fat cells directly and stimulates their destruction, rather than relying primarily on a…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
